3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Paclitaxel
268
Carboplatin
264
Cisplatin
194
Bevacizumab
135
pembrolizumab
99
Surveys and Questionnaires
84
Radiotherapy
77
Cyclophosphamide
75
olaparib
67
Blood Specimen Collection
65
Drug Therapy
62
Hyperthermic Intraperitoneal Chemotherapy
60
Gemcitabine
60
niraparib
56
Topotecan
56
Brachytherapy
54
liposomal doxorubicin
52
Taxes
47
Docetaxel
46
Magnetic Resonance Spectroscopy
43
Letrozole
36
Cytoreduction Surgical Procedures
36
Filgrastim
33
Biopsy
33
Surgical Procedures, Operative
32
durvalumab
31
Specimen Handling
31
Doxorubicin
31
Nivolumab
30
Albumin-Bound Paclitaxel
28
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
nanocis
×
Gynecologic
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled
NCT02667925
2016-10-11
ISOTOVE
Centre Jean Perrin
Phase NA
Withdrawn